Author:
Bayram İbrahim,Erbey Fatih,Kömür Mustafa,Tanyeli Atila
Reference14 articles.
1. Golub TR and Arceci RJ. Acute myelogenous leukemia. In Pizzo PA and Poplack DG: Principles and Practice of Pediatric Oncology. Lippincott Williams and Wilkins Company, Philadelphia, 4th edt. 2006; pp 591-644.
2. Sasmaz I, Tanyeli A, Bayram I, et al. The results of treatment with idarubicin in childhood acute nonlymphoblastic leukemia. Turk J Pediatr 2004; 46:32-7.
3. Heuvel-Elbrink MVA. Acute myeloid leukemia. In: Pinkerton R, Plowman PN, Pieters R. Paediatric oncology, third ed., Oxford University pres, 2004; 203-29.
4. Stahnke K, Boos J, Bender-Gotze C, Ritter J, Zimmermann M, Creutzig U. Duration of first remission predicts remission rates and long-term survival in children with relapsed acute myelogenous leukemia. Leukemia 1998;12:1534-8.
5. Thalhammer F, Geissler K, Jager U, et al. Duration of second complete remission in patients with acute myeloid leukemia treated with chemotherapy: a retrospective single-center study. Ann Hematol 1996;72:216-22.